Literature DB >> 3499490

Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET.

M Kushner1, M Tobin, A Alavi, J Chawluk, M Rosen, F Fazekas, J Alavi, M Reivich.   

Abstract

We studied cerebellar metabolism in 118 subjects including young and elderly controls and patients suffering from stroke, supratentorial brain tumor and Alzheimer's disease using fluorine-18 fluorodeoxyglucose ([18F]FDG) and position emission tomography (PET). Alzheimer's disease and normal aging did not alter mean cerebellar metabolism. In stroke and tumor mean cerebellar metabolism was lower in the hemisphere contralateral to the supratentorial lesion. In tumor bilaterally significant reductions in absolute cerebellar metabolism also were noted, unlike stroke. Primary sensory stimulation did not alter absolute or relative cerebellar metabolism. These results show that absolute and relative values for cerebellar metabolism vary depending on the process under study. Thus analysis schemes employing normalization of regional metabolic data to cerebellar values may be subject to error.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499490

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  A comparative technetium 99m hexamethylpropylene amine oxime SPET study in different types of dementia.

Authors:  M O Habert; U Spampinato; J L Mas; M L Piketty; M C Bourdel; J de Recondo; P Rondot; S Askienazy
Journal:  Eur J Nucl Med       Date:  1991

2.  Empirical derivation of the reference region for computing diagnostic sensitive ¹⁸fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample.

Authors:  Jerod M Rasmussen; Anita Lakatos; Theo G M van Erp; Frithjof Kruggel; David B Keator; James T Fallon; Fabio Macciardi; Steven G Potkin
Journal:  Biochim Biophys Acta       Date:  2011-09-19

3.  Association between functional connectivity hubs and brain networks.

Authors:  Dardo Tomasi; Nora D Volkow
Journal:  Cereb Cortex       Date:  2011-01-31       Impact factor: 5.357

4.  Healthy brain ageing assessed with 18F-FDG PET and age-dependent recovery factors after partial volume effect correction.

Authors:  Stijn Bonte; Pieter Vandemaele; Stijn Verleden; Kurt Audenaert; Karel Deblaere; Ingeborg Goethals; Roel Van Holen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-23       Impact factor: 9.236

5.  Dynamic brain glucose metabolism identifies anti-correlated cortical-cerebellar networks at rest.

Authors:  Dardo G Tomasi; Ehsan Shokri-Kojori; Corinde E Wiers; Sunny W Kim; Şukru B Demiral; Elizabeth A Cabrera; Elsa Lindgren; Gregg Miller; Gene-Jack Wang; Nora D Volkow
Journal:  J Cereb Blood Flow Metab       Date:  2017-05-23       Impact factor: 6.200

6.  Age and sex differences in the cerebellum and the ventral pons: a prospective MR study of healthy adults.

Authors:  N Raz; F Gunning-Dixon; D Head; A Williamson; J D Acker
Journal:  AJNR Am J Neuroradiol       Date:  2001 Jun-Jul       Impact factor: 3.825

7.  Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.

Authors:  Sepideh Shokouhi; Desmond Campbell; Aaron B Brill; Harry E Gwirtsman
Journal:  Brain Pathol       Date:  2016-09       Impact factor: 6.508

8.  Comparison of I-123 IMP and Tc-99m HMPAO SPECT studies with PET in dementia.

Authors:  Y Kuwabara; Y Ichiya; M Otsuka; T Tahara; T Fukumura; R Gunasekera; A Ichimiya; K Masuda
Journal:  Ann Nucl Med       Date:  1990-11       Impact factor: 2.668

9.  Quantification of functional deficit in Alzheimer's disease using a computer-assisted mapping program for 99mTc-HMPAO SPECT.

Authors:  H Karbe; A Kertesz; J Davis; B J Kemp; F S Prato; R L Nicholson
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

10.  Cerebrocerebellar relationships in normal subjects and patients with dementia of the Alzheimer type: a SPECT study.

Authors:  H Hanyu; H Arai; S Abe; T Iwamoto; M Takasaki; H Katsunuma; T Suzuki; K Abe; S Amino
Journal:  Ann Nucl Med       Date:  1993-02       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.